Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
This phase II multi-centered, randomized controlled trial of mechanical ventilation directed by esophageal pressure measurement will test the primary hypothesis that using a strategy of maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient survival.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Esophageal-pressure guided mechanical ventilation
- other: High PEEP mechanical ventilation
Eligibility
Inclusion Criteria:
- Acute onset of ARDS as defined by the Berlin Consensus Conference definitions:
1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio < 200 mmHg
2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities not
present for more than 7 days
3. Respiratory failure not fully explained by cardiac failure or fluid overload
4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O
- Age 16 years or older
- Duration of ARDS 36 hours or less from meeting final Berlin criterion.
Exclusion Criteria:
- Received mechanical ventilation more than 96 hours
- Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal
trauma, recent esophageal surgery or other contraindication for nasogastric tube
placement
- Severe coagulopathy (platelet count < 5000/microliter or INR > 4)
- History of lung transplantation
- Elevated intracranial pressure or conditions where hypercapnia-induced elevations in
intracranial pressure should be avoided
- Evidence of active air leak from the lung
- not committed to full support
- Participation in other intervention trials for ARDS or for sepsis within the past 30
days.
- Neuromuscular disease that impairs ability to ventilate spontaneously
- Severe chronic liver disease, defined as Child-Pugh Score of ≥12
- Treating clinician refusal, or unwillingness to commit to controlled ventilation for
at least 24 hours
- Inability to get informed consent from the patient or surrogate.
- Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone
positioning, high frequency oscillation). This does not exclude cases where these
therapies were used as the initial mode of ventilation
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joseph Levitt, MD
I'm interested
Psoriasis Clinical Trials
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
This phase II multi-centered, randomized controlled trial of mechanical ventilation directed by esophageal pressure measurement will test the primary hypothesis that using a strategy of maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient survival.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Esophageal-pressure guided mechanical ventilation
- other: High PEEP mechanical ventilation
Eligibility
Inclusion Criteria:
- Acute onset of ARDS as defined by the Berlin Consensus Conference definitions:
1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio < 200 mmHg
2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities not
present for more than 7 days
3. Respiratory failure not fully explained by cardiac failure or fluid overload
4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O
- Age 16 years or older
- Duration of ARDS 36 hours or less from meeting final Berlin criterion.
Exclusion Criteria:
- Received mechanical ventilation more than 96 hours
- Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal
trauma, recent esophageal surgery or other contraindication for nasogastric tube
placement
- Severe coagulopathy (platelet count < 5000/microliter or INR > 4)
- History of lung transplantation
- Elevated intracranial pressure or conditions where hypercapnia-induced elevations in
intracranial pressure should be avoided
- Evidence of active air leak from the lung
- not committed to full support
- Participation in other intervention trials for ARDS or for sepsis within the past 30
days.
- Neuromuscular disease that impairs ability to ventilate spontaneously
- Severe chronic liver disease, defined as Child-Pugh Score of ≥12
- Treating clinician refusal, or unwillingness to commit to controlled ventilation for
at least 24 hours
- Inability to get informed consent from the patient or surrogate.
- Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone
positioning, high frequency oscillation). This does not exclude cases where these
therapies were used as the initial mode of ventilation
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joseph Levitt, MD
I'm interested
Dermatology Clinical Trials
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
This phase II multi-centered, randomized controlled trial of mechanical ventilation directed by esophageal pressure measurement will test the primary hypothesis that using a strategy of maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient survival.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Esophageal-pressure guided mechanical ventilation
- other: High PEEP mechanical ventilation
Eligibility
Inclusion Criteria:
- Acute onset of ARDS as defined by the Berlin Consensus Conference definitions:
1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio < 200 mmHg
2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities not
present for more than 7 days
3. Respiratory failure not fully explained by cardiac failure or fluid overload
4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O
- Age 16 years or older
- Duration of ARDS 36 hours or less from meeting final Berlin criterion.
Exclusion Criteria:
- Received mechanical ventilation more than 96 hours
- Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal
trauma, recent esophageal surgery or other contraindication for nasogastric tube
placement
- Severe coagulopathy (platelet count < 5000/microliter or INR > 4)
- History of lung transplantation
- Elevated intracranial pressure or conditions where hypercapnia-induced elevations in
intracranial pressure should be avoided
- Evidence of active air leak from the lung
- not committed to full support
- Participation in other intervention trials for ARDS or for sepsis within the past 30
days.
- Neuromuscular disease that impairs ability to ventilate spontaneously
- Severe chronic liver disease, defined as Child-Pugh Score of ≥12
- Treating clinician refusal, or unwillingness to commit to controlled ventilation for
at least 24 hours
- Inability to get informed consent from the patient or surrogate.
- Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone
positioning, high frequency oscillation). This does not exclude cases where these
therapies were used as the initial mode of ventilation
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joseph Levitt, MD
I'm interested
Pediatric Dermatology Clinical Trials
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
This phase II multi-centered, randomized controlled trial of mechanical ventilation directed by esophageal pressure measurement will test the primary hypothesis that using a strategy of maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient survival.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Esophageal-pressure guided mechanical ventilation
- other: High PEEP mechanical ventilation
Eligibility
Inclusion Criteria:
- Acute onset of ARDS as defined by the Berlin Consensus Conference definitions:
1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio < 200 mmHg
2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities not
present for more than 7 days
3. Respiratory failure not fully explained by cardiac failure or fluid overload
4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O
- Age 16 years or older
- Duration of ARDS 36 hours or less from meeting final Berlin criterion.
Exclusion Criteria:
- Received mechanical ventilation more than 96 hours
- Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal
trauma, recent esophageal surgery or other contraindication for nasogastric tube
placement
- Severe coagulopathy (platelet count < 5000/microliter or INR > 4)
- History of lung transplantation
- Elevated intracranial pressure or conditions where hypercapnia-induced elevations in
intracranial pressure should be avoided
- Evidence of active air leak from the lung
- not committed to full support
- Participation in other intervention trials for ARDS or for sepsis within the past 30
days.
- Neuromuscular disease that impairs ability to ventilate spontaneously
- Severe chronic liver disease, defined as Child-Pugh Score of ≥12
- Treating clinician refusal, or unwillingness to commit to controlled ventilation for
at least 24 hours
- Inability to get informed consent from the patient or surrogate.
- Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone
positioning, high frequency oscillation). This does not exclude cases where these
therapies were used as the initial mode of ventilation
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joseph Levitt, MD
I'm interested
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
This phase II multi-centered, randomized controlled trial of mechanical ventilation directed by esophageal pressure measurement will test the primary hypothesis that using a strategy of maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient survival.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Esophageal-pressure guided mechanical ventilation
- other: High PEEP mechanical ventilation
Eligibility
Inclusion Criteria:
- Acute onset of ARDS as defined by the Berlin Consensus Conference definitions:
1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio < 200 mmHg
2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities not
present for more than 7 days
3. Respiratory failure not fully explained by cardiac failure or fluid overload
4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O
- Age 16 years or older
- Duration of ARDS 36 hours or less from meeting final Berlin criterion.
Exclusion Criteria:
- Received mechanical ventilation more than 96 hours
- Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal
trauma, recent esophageal surgery or other contraindication for nasogastric tube
placement
- Severe coagulopathy (platelet count < 5000/microliter or INR > 4)
- History of lung transplantation
- Elevated intracranial pressure or conditions where hypercapnia-induced elevations in
intracranial pressure should be avoided
- Evidence of active air leak from the lung
- not committed to full support
- Participation in other intervention trials for ARDS or for sepsis within the past 30
days.
- Neuromuscular disease that impairs ability to ventilate spontaneously
- Severe chronic liver disease, defined as Child-Pugh Score of ≥12
- Treating clinician refusal, or unwillingness to commit to controlled ventilation for
at least 24 hours
- Inability to get informed consent from the patient or surrogate.
- Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone
positioning, high frequency oscillation). This does not exclude cases where these
therapies were used as the initial mode of ventilation
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joseph Levitt, MD
I'm interested
EPVent 2- A Phase II Study of Mechanical Ventilation Directed by Transpulmonary Pressures
This phase II multi-centered, randomized controlled trial of mechanical ventilation directed by esophageal pressure measurement will test the primary hypothesis that using a strategy of maintaining a minimal but positive transpulmonary pressure (Ptp = airway pressure minus pleural pressure) throughout the ventilatory cycle will lead to an improvement in patient survival.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- other: Esophageal-pressure guided mechanical ventilation
- other: High PEEP mechanical ventilation
Eligibility
Inclusion Criteria:
- Acute onset of ARDS as defined by the Berlin Consensus Conference definitions:
1. Hypoxemic respiratory failure with PaO2 / FIO2 ratio < 200 mmHg
2. b) Bilateral alveolar/interstitial infiltrates on chest x-ray, with opacities not
present for more than 7 days
3. Respiratory failure not fully explained by cardiac failure or fluid overload
4. Intubation on controlled ventilation and receiving PEEP ≥ 5 cm H2O
- Age 16 years or older
- Duration of ARDS 36 hours or less from meeting final Berlin criterion.
Exclusion Criteria:
- Received mechanical ventilation more than 96 hours
- Recently treated or bleeding varices, esophageal stricture, hematemesis, esophageal
trauma, recent esophageal surgery or other contraindication for nasogastric tube
placement
- Severe coagulopathy (platelet count < 5000/microliter or INR > 4)
- History of lung transplantation
- Elevated intracranial pressure or conditions where hypercapnia-induced elevations in
intracranial pressure should be avoided
- Evidence of active air leak from the lung
- not committed to full support
- Participation in other intervention trials for ARDS or for sepsis within the past 30
days.
- Neuromuscular disease that impairs ability to ventilate spontaneously
- Severe chronic liver disease, defined as Child-Pugh Score of ≥12
- Treating clinician refusal, or unwillingness to commit to controlled ventilation for
at least 24 hours
- Inability to get informed consent from the patient or surrogate.
- Use of rescue therapies for prior to enrollment (e.g. nitric oxide, ECMO, prone
positioning, high frequency oscillation). This does not exclude cases where these
therapies were used as the initial mode of ventilation
Ages Eligible for Study
16 Years - N/A
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Joseph Levitt, MD
I'm interested